By Ben James (December 29, 2008, 12:00 AM EST) -- Schering Corp., Sepracor Inc. and Dr. Reddy's Laboratories Ltd. have struck settlement deals that should resolve litigation and allow the India-based generics maker to enter the $362 million annual U.S. market for the allergy drug Clarinex in 2012, Dr. Reddy's said.
Dr. Reddy's said the deals resolve all pending suits brought against Dr. Reddy's by Schering and Sepracor over Clarinex in the U.S. District Court for the District of New Jersey, adding that total U.S. sales for all formulations of Clarinex in 2007 were $362 million.
The specific terms of the agreements have not been disclosed, and the deals are subject...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!